Centro de Investigación Biomédica en Red de Cáncer-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2023

  1. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

2022

  1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

  2. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

2021

  1. Immunologic characterization of COVID-19 patients with hematological cancer

    Haematologica

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

2020

  1. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer

    European Journal of Cancer, Vol. 135, pp. 173-182

2019

  1. Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells

    Cancer cell, Vol. 36, Núm. 6, pp. 613-629

  2. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

2018

  1. A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

  2. Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15

    OncoImmunology, Vol. 7, Núm. 2

2017

  1. Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells

    Immunology and Cell Biology, Vol. 95, Núm. 4, pp. 347-355